Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,986
  • Shares Outstanding, K 29,327
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,940 K
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.41
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +36.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +23.12%
on 04/17/19
4.73 -3.17%
on 04/24/19
+0.57 (+14.21%)
since 03/22/19
3-Month
3.72 +23.12%
on 04/17/19
5.44 -15.81%
on 02/27/19
+0.72 (+18.65%)
since 01/24/19
52-Week
3.22 +42.24%
on 12/26/18
13.91 -67.07%
on 06/15/18
-5.39 (-54.06%)
since 04/24/18

Most Recent Stories

More News
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial...

CRVS : 4.58 (+5.77%)
Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the...

CRVS : 4.58 (+5.77%)
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation...

CRVS : 4.58 (+5.77%)
Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it...

CRVS : 4.58 (+5.77%)
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment...

CRVS : 4.58 (+5.77%)
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Company on track to submit Investigational New Drug application for CPI-818 in early 2019

CRVS : 4.58 (+5.77%)
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms now enrolling patients at U.S. sites

CRVS : 4.58 (+5.77%)
Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher

Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

CRVS : 4.58 (+5.77%)
ZIOP : 4.16 (unch)
Corvus: 1Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Thursday reported a loss of $14.3 million in its first quarter.

CRVS : 4.58 (+5.77%)
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial...

CRVS : 4.58 (+5.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRVS with:

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

2nd Resistance Point 4.92
1st Resistance Point 4.75
Last Price 4.58
1st Support Level 4.39
2nd Support Level 4.20

See More

52-Week High 13.91
Fibonacci 61.8% 9.83
Fibonacci 50% 8.56
Fibonacci 38.2% 7.30
Last Price 4.58
52-Week Low 3.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar